Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia

Biresaw Demile¹,², Amare Zenebu², Haile Shewaye², Siqing Xia³ and Awoke Guadie³,⁴*

Abstract

Background: Ethiopia is one of the world health organization defined higher tuberculosis (TB) burden countries where the disease remains a massive public health threat. This study aimed to identify the prevalence and associated factors of multidrug-resistant tuberculosis (MDR-TB) using all armed force and civilian TB attendants in a tertiary level armed force hospital, where data for MDR-TB are previously unpublished.

Methods: Cross-sectional study was conducted from September 2014 to August 2015 in a tertiary level Armed Force Referral and Teaching Hospital (AFRTH), Ethiopia. Armed force members (n = 251) and civilians (n = 130) which has been undergone TB diagnosis at AFRTH were included. All the specimens collected were subjected to microscopic smear observation, culture growth and drug susceptibility testing. Data were analyzed using statistical package for social sciences following binary logistic regression and Chi-square. P-values < 0.05 were considered statistically significant.

Results: Among 381 TB patients, 355 (93.2%) new and 26 (6.8%) retreatment cases were identified. Culture and smear positive TB cases were identified in 297 (77.9%) and 252 (66.1%) patients, respectively. The overall prevalence of MDR-TB in AFRTH was found 1.8% (1.3% for armed force members and 0.5% for civilian patients) all of which were previously TB treated cases. The entire treatment success rates were 92.6% achieved highest in the armed force (active and pension) than the civilian patients. The failure and dead cases were also found 2.5 and 4.6%, respectively. Using bivariate analysis, category of attendants and TB contact history were strong predictors of MDR-TB in armed force and civilian patients. Moreover, human immunodeficiency virus (HIV) infection also identified a significant (OR = 14.6; 95% CI = 2.3–92.1; p = 0.004) predicting factor for MDR-TB in armed force members. However, sex, age and body mass index were not associated factor for MDR-TB.

Conclusions: In AFRTH, lower prevalence of MDR-TB was identified in armed force and civilian patients that were significantly associated with category of attendants, HIV infection and TB contact history. Considering armed force society as one segment of population significantly helps to plan a better MDR-TB control management, especially for countries classified as TB high burden country.

Keywords: Tuberculosis, Armed force, Ethiopia, Drug susceptibility, Risk factors

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis* (*M. tuberculosis*) complex which usually affects the lung [1]. The bacteria are transmitted via close contact with an infected individual who is actively spreading the bacteria through coughing [2]. Once inhaled, the infection remains latent for decades in 90 to 95% healthy adult [1–3]. However, illness of latent TB manifested only when the bacteria become active. There are many factors that contribute the latent TB bacteria become active including human immunodeficiency virus (HIV), older age, diabetics, close contact with an active case of TB disease and other immuno-compromising illness conditions [1, 4].

Although TB is an old disease with many efforts to treat and control, still it remains the main cause of morbidity for millions of people each year [1, 3]. According to World Health Organization (WHO) estimates showed that there were almost 9.6 (5.4 men, 3.2 women and 1.0 children) million new TB cases globally in 2014, of which 1.5 million cases were accounted TB deaths [5]. The same WHO report also showed that 86% of TB infection is from South-East Asia and Western Pacific (58%) and African (28%) regions. The presence of relatively higher HIV patient in these regions significantly contributed an increased incidence of TB [6]. Ethiopia is one of the WHO defined higher TB burden countries where the disease remains a massive public health threat and an economic burden. World Health Organization in 2016 listed Ethiopia 10th out of the 30 high TB priority countries in the globe [1].

Based on WHO recommended six-month standard course of medication, several countries treat TB disease using four first-line (rifampin, isoniazid, pyrazinamide and ethambutol) anti-TB drugs [2, 7, 8]. When *M. tuberculosis* becomes resistant to treatment with at least the two first-line drugs (i.e, isoniazid and rifampin), the condition is known as multidrug-resistant tuberculosis (MDR-TB) [1, 3, 9]. Previous studies mentioned that *M. tuberculosis* develops various drug-resistance mechanisms by using its special cellular structure and metabolic system [9, 10]. For instance, the unique structures like mycolic acid (as part of the cell wall) and trans-membrane protein help the *M. tuberculosis* to restrict entry of drug molecules to the cell, and to pump out antibiotics from the cell, respectively [10, 11]. The *M. tuberculosis* also utilizes different enzymatic strategies to alter the structure of drug synthesis target sites (such as ribosomes and deoxyribonucleic acid) and thereby avoid the action of antibiotics [12]. Moreover, there are also reports that mentioned the ability of *M. tuberculosis* directly modify the anti-TB drug into another form which in turn leads to inactivate the target drug compound action designed for its specific cellular site [10–13]. Inadequate treatment (due to shortage of drug, increasing cost of drug and physician errors) and inadequate adherence (such as poor compliance, alcoholism, drug addiction, length of treatment and adverse drug reactions) have been also identified as a drug resistance enhancing mechanisms by creating a selective pressure for a rapid evolution of *M. tuberculosis* [14–17].

Globally, 3.5% of new and 20.5% of previously treated TB patients were estimated to have had MDR-TB [1]. Sub-Saharan Africa represents 14% of the global burden of new MDR-TB cases [18]. World Health Organization in 2016 listed Ethiopia 8th out of 30 high MDR-TB burden countries in the world with a prevalence of 2.7% (1.5–4.0) in newly and 14.0% (3.6–25.0) in previously treated TB patients. Like Ethiopia which is listed 3rd, other six countries in Africa including (new/retreatment % accordingly) Angola (2.6/18%), DR Congo (2.2/17%), Kenya (1.3/9.4%), Nigeria (4.3/25%), Somalia (8.7/47%) and Zimbabwe (4.6/14%) also listed among the 30 high MDR-TB burden countries in the world [1]. Although MDR-TB is a growing concern in Africa where limited resource exists, it is largely under-reported [18, 19]. In Ethiopia, many of the MDR-TB patients are remain undiagnosed due to the low socioeconomic status of the population, lack of awareness and inaccessibility of health service. For instance, WHO in 2012 estimated that the number of patients in Ethiopia tested for MDR-TB was <1% of new and <4% of retreatment cases [5].

There are small numbers of MDR-TB studies in different regions of Ethiopia [16, 20–22], however, most of these surveys were restricted only to civilian patients and civilian hospitals. To the best of our knowledge, there is no published information about the status of TB and MDR-TB concerning armed force as one segment of the population in Ethiopia. This condition significantly compromises the MDR-TB control efforts. Therefore, this study has been designed to evaluate the prevalence and risk factors of MDR-TB using armed force and civilian patients in a tertiary level Armed Force Referral and Teaching Hospital (AFRTH) Addis Ababa, Ethiopia. The subjects were from Ministry of Defense members (active military and pension) and civilian clients which have got service from AFRTH.

Methods

Study area

The study was conducted at AFRTH which is located in Addis Ababa, the capital city of Ethiopia. It is the only referral and teaching military hospital of the country at the rank of tertiary level. It is organized under Health Main Directorate (HMD), Ministry of Defense.

Armed Force Referral and Teaching Hospital provides medical services to members of the Ethiopian defense forces. It accepts referral case from all secondary level (Eastern, Central, North and South-western) command
Definition of TB cases and treatment outcome

According to the standard definitions of NTLCP guideline of Ethiopia [7], the following case and treatment outcome definitions were used in the current study. The following are case definitions: (i) new case is used if a patient who never had treatment for TB or has been on previous anti-TB treatment for less than 4 wk in the past, (ii) relapse if a patient declared cured or whose treatment was completed of any form of TB in the past, but who reports back to the health service and is now found to be microscopic smear positive or culture positive, (iii) treatment failure if a patient who is smear positive at the end of the fifth month or later, after commencing and it also includes a patient who was initially sputum smear negative but who becomes smear positive during treatment, (iv) return after default if a patient previously recorded as defaulted from treatment and returns to the health facility with smear positive sputum, and (v) others if a patient who does not fit in any of the above mentioned categories (e.g, smear negative pulmonary TB case who returns after default, extapulmonary TB case returning after default and previously treated TB patients with an unknown outcome of that previous treatment).

According to NTLCP guideline [7], the following treatment outcome definitions were also used in the current study: (i) cured if patients have finished treatment with negative bacteriology result at the end of treatment, (ii) treatment completed if the patient finished treatment, but without bacteriology result at the end of treatment, (iii) treatment failure if a TB patient remains smear positive at 5 mo follow-up despite correct intake of medication, (iv) defaulted treatment if the patients who interrupted their treatment for two consecutive months or more than 2 mo after registration, (v) died if the patient died from any cause during the course of treatment, (vi) transfer out if the patient treatment result is unknown due to transfer to another health facility, and (vi) treatment success is used defined as the sum of cured and completed treatments.

Study design, data collection and laboratory sputum sample processing

A cross-sectional study was conducted following the most recent WHO guidelines for surveillance of drug-resistance in TB [23]. In this study, all patients who diagnosed TB in AFRTH between September 2014 to August 2015 and whose information found to be complete and qualify the NTLCP guidelines had been included. The study subjects include direct register patients at AFRTH (armed force members and civilians) and those referred from secondary level armed hospitals (armed force members only) located all over the country. As a result, our study population especially the armed force members appears to be a representative sample of all military members at risk for TB that are located all over Ethiopia.

In AFRTH, the suspected TB patients were first identified through examining signs and symptoms, chest x-ray and prior history of TB. Although a large number of patients had been registered in the AFRTH-TB Clinic, those who failed to qualify the preliminary examination have not been included in the current study. Among 389 cases qualified for preliminary examination, 8 suspected TB cases were also excluded due to incomplete information.

Demographic data such as gender, age, HIV status, the category of attendants and TB contact history were collected from the patient record books. In addition, routine data were obtained from AFRTH laboratory reports for sputum smear microscopy, culture growth and drug susceptibility testing (DST). The clinical samples were processed using the N-acetyl-L-cysteine NaOH (NALC-NaOH) method. The processed samples were suspended in 1000 mL neutral sterile phosphate buffer and then 100 mL of resuspended pellet was inoculated onto Lowenstein–Jensen (LJ) medium slants. M. tuberculosis was confirmed in cultures using measurements of growth rate, colony morphology, pigmentation and commercial biochemical tests. The biochemical testing (niacin assay, nitrate reduction, and catalase tests) was used to identify the isolated Mycobacterium once they were categorized into a preliminary subgroup based on their growth characteristics [24]. All isolates of M. tuberculosis were subjected to DST using concentration method. Drug susceptibility testing for the four (rifampin, isoniazid, streptomycin and ethambutol) first-line anti-TB drug was performed according to WHO guidelines [23]. Smear for microscopic examination was also stained using the Ziehl–Neelsen method and results were reported as smear positive and negative.

The AFRTH laboratory was subjected to quality control through WHO guideline [23]. Drug susceptibility testing quality control was done using standard strains of M. tuberculosis (H37Rv). All data included here were reported by qualified laboratory technicians and physicians.

Statistical analysis

The data were analyzed using Epi Info 6, Excel 2010 and statistical package for the social sciences (SPSS) version 20.0 (IBM, NY, USA). A total of 389 patient information's
were initially enter into the data system, however, eight (2.0%) patients whose information were found to be incomplete and excluded during data analysis. Either binary logistic regression or Chi-square (likelihood ratio) statistics were used to assess the possible risk factors associated with the dependent variable MDR-TB and the independent variables such as sex, age, body mass index, patient categories, TB contact history and HIV infection. Two-sided \( p \)-values were considered significant when the value was less than 0.05.

**Results**

**Demography, culture and drug susceptibility tests**

As shown in Table 1, a total of 389 clinically diagnosed TB patients were enrolled in AFRTH, of which 98% cases were included in this study. Eight (2.0%) cases were excluded for MTB culture growth, microscopic smear observation and drug sensitivity tests due to incomplete demography data (\( n = 5 \)) and contamination (\( n = 3 \)). The new and retreatment TB cases included were found 355 (93.2%) and 26 (6.8%), respectively. Based on the category of patients registered in AFRTH, active armed force, pension and civilians were found 216 (56.7%), 35 (9.2) and 130 (34.1%), respectively.

As shown in Table 2, the proportion of men and women patients were found 273 (71.7%) and 108 (28.3%), respectively resulting male to female ratio to be 2.5 to 1. The age of the study participants varies from 18 to 96 years with a median age of 34 years. The mean age of the patients was 36.76 ± 13.84 years, of which 288 (75.6%) patients were in the age range of 18–45 years (most in the active armed force).

Among 381 TB suspected patients, 26 (6.8%) patients have TB contact history, particularly attendants from the armed force was higher (\( n = 20 \)). Culture growth on LJ media was observed from 297 (77.9%) specimens. The pension sputum samples almost all (97.1%) found culture positive. However, in the active armed force and civilians specimens, the culture positive results were below 80%. Compared with culture positive samples, overall 66.1% (\( n = 252 \)) of microscopic smear TB positive samples were identified which has been relatively lower in all patient groups (69.2% for civilian, 64.4% for active and 65.7% for pension armed force members) than the corresponding culture growth results. The DST results showed that 7 (1.8%) specimens identified as MDR-TB cases and 374 (98.2%) specimens non-MDR-TB cases. The number of civilian and armed force members with MDR-TB was identified in 2 (0.5%) and 5 (1.3%) patients, respectively in which all patients were previously treated TB case (Table 2). There were no new MDR-TB cases identified, rather all MDR-TB patients have been found to be a failure (\( n = 1 \)) and relapse (\( n = 6 \)) cases (Table 2).

In AFRTH, all smear positive (\( n = 252 \)) and negative (\( n = 129 \)) patients were treated with first-line TB drugs. Except for 97 (25.5%) cases that have been transferred out (results unknown), most (74.5%) TB patient outcomes were known. Most of the TB patients completed (56.7%) the treatment, while 12.6, 3.4 and 1.8% were a cure, dead and failure cases, respectively. All the dead cases (\( n = 13 \)) were newly diagnosed patients which were identified from active armed force members (\( n = 11 \)) and civilian patients (\( n = 2 \)). Interestingly, in the current study there was no defaulter treatment outcome seen either in civilian or armed force patients (Table 2). Compared with Ethiopian national TB treatment success rate (84.0%) [1], the current study treatment success rate (69.3%) has been found lower due to most of the transfer out cases (25.5%), which is expected from AFRTH that accepts referred patients from all secondary level (Eastern, Central, North and South-western) command referral hospitals located all over the country.

Although all (\( n = 381 \)) TB patients requested to give blood for HIV test, most (\( n = 355 \)) accepted the offer, particularly all the pension attendants (Table 2). However, 16 (4.2%) civilian patients and 10 (2.6%) active armed force members rejected the offer. Among 114 civilians, 206 active and 35 pension TB patients who accepted the HIV test, respectively 9, 15 and 10 samples were identified HIV positive. Among HIV test positive (\( n = 34 \)) TB patients, 28 (82.4%) patients started taking

| Classification | Total-patients | TB-new patients | TB-previouly treated patients |
|----------------|----------------|----------------|------------------------------|
| Number %      | Number %       | Number %       | Number %                    |
| Total TB-patients | 389 100  | 362 100  | 27 100  |
| TB-patients excluded | 8 2.0  | 7 1.9  | 1 3.7  |
| TB-patients included | 381 98.0  | 355 98.1  | 26 96.3  |
| Category of attendants |         |             |                              |
| Armed force-Active | 216 56.7  | 203 57.2  | 13 50.0  |
| Armed force-Pension | 35 9.2  | 26 7.3  | 9 34.6  |
| Civil | 130 34.1  | 126 35.5  | 4 15.4  |
Table 2: General demographic and clinical findings of civilian and armed force patients in AFRTH

| Variables                        | Total cases (n = 381) | Civilian (n = 130) | Armed force members |
|----------------------------------|-----------------------|--------------------|---------------------|
|                                  | No   | %    | No   | %    | No   | %    | No   | %    |
| **Sex**                          |       |      |       |      |       |      |       |      |
| Female                           | 108  | 28.3 | 63   | 48.5 | 42   | 19.4 | 4    | 11.4 |
| Male                             | 273  | 71.7 | 67   | 51.5 | 174  | 80.6 | 31   | 88.6 |
| **Age (year)**                   |       |      |       |      |       |      |       |      |
| 18–44                            | 288  | 75.6 | 96   | 73.8 | 192  | 88.9 | 0    | 0    |
| ≥45                              | 93   | 24.4 | 34   | 26.2 | 24   | 11.1 | 35   | 100  |
| **Body mass index (kg/m²)**      |       |      |       |      |       |      |       |      |
| < 18.5                           | 39   | 10.2 | 15   | 11.5 | 22   | 10.2 | 2    | 5.7  |
| 18.5–25                          | 217  | 57.0 | 67   | 51.5 | 129  | 59.7 | 21   | 60.0 |
| > 25                             | 125  | 32.8 | 48   | 37.0 | 65   | 30.1 | 12   | 34.3 |
| **History of TB contact**        |       |      |       |      |       |      |       |      |
| Yes                              | 26   | 6.8  | 6    | 4.6  | 15   | 6.9  | 5    | 14.3 |
| No                               | 355  | 93.2 | 124  | 95.4 | 201  | 93.1 | 30   | 85.7 |
| **Culture growth on LJ media**   |       |      |       |      |       |      |       |      |
| Positive                         | 297  | 77.9 | 93   | 71.5 | 170  | 78.7 | 34   | 97.1 |
| Negative                         | 84   | 22.1 | 37   | 28.5 | 46   | 21.3 | 1    | 2.9  |
| **Microscopic smear observation**|       |      |       |      |       |      |       |      |
| Positive                         | 252  | 66.1 | 90   | 69.2 | 139  | 64.4 | 23   | 65.7 |
| Negative                         | 129  | 33.9 | 40   | 30.8 | 77   | 35.6 | 12   | 34.3 |
| **Drug susceptibility testing**  |       |      |       |      |       |      |       |      |
| MDR-TB                           | 7    | 1.8  | 2    | 1.5  | 2    | 0.9  | 3    | 8.6  |
| Non-MDR-TB                       | 374  | 98.2 | 128  | 98.5 | 214  | 99.1 | 32   | 91.4 |
| **TB-patient categories at start**|       |      |       |      |       |      |       |      |
| New                              | 355  | 93.2 | 126  | 97.0 | 203  | 94.0 | 26   | 74.2 |
| Relapse                          | 6    | 1.6  | 2    | 1.5  | 7    | 3.2  | 7    | 200  |
| Failure                          | 1    | 0.3  | 0    | 0.0  | 1    | 0.5  | 0    | 0    |
| Return after default             | 2    | 0.6  | 0    | 0.0  | 1    | 0.5  | 1    | 2.9  |
| Others                           | 17   | 4.3  | 2    | 1.5  | 4    | 1.8  | 1    | 2.9  |
| **TB-treatment outcome**         |       |      |       |      |       |      |       |      |
| Complete                         | 216  | 56.7 | 69   | 53.1 | 121  | 56.0 | 26   | 74.3 |
| Cure                             | 48   | 12.6 | 5    | 3.8  | 41   | 19.0 | 2    | 5.7  |
| Dead                             | 13   | 3.4  | 2    | 1.5  | 11   | 5.1  | 0    | 0    |
| Failure                          | 7    | 1.8  | 1    | 0.8  | 1    | 0.5  | 5    | 14.3 |
| Transfer out                     | 97   | 25.5 | 53   | 40.8 | 42   | 19.4 | 2    | 5.7  |
| **HIV result**                   |       |      |       |      |       |      |       |      |
| Positive                         | 34   | 8.9  | 9    | 6.9  | 15   | 7.0  | 10   | 28.6 |
| Negative                         | 321  | 84.3 | 105  | 80.8 | 191  | 88.4 | 25   | 71.4 |
| Not tested                       | 26   | 6.8  | 16   | 12.3 | 10   | 4.6  | 0    | 0    |
antiretroviral therapy (ART). However, one civilian, three active military and two pension attendants didn’t start the ART drug (Table 2).

Multidrug-resistant tuberculosis risk factors
The relationship between individual exposure variables (category of attendants, gender, age, body mass index, TB contact history and HIV status) and the dependent variables (MDR-TB status) were shown in Tables 3 and 4. In general, the category of attendants was the predicting factor ($p = 0.029$) for MDR-TB in AFRTH patients (Table 3). Compared with active armed force members (2/216 = 0.9%) and civilian attendants (2/130 = 1.5%), pensions have shown significant ($p = 0.013$) higher (3/35 = 8.6%) value of MDR-TB positive results. The occurrence of lower MDR-TB positive than MDR-TB negative results was also found a strong predicting factor ($p = 0.007$) for the category of attendants.

As shown in Table 4, HIV infection result (OR = 14.6; 95% CI = 2.3–92.1; $p = 0.004$) and TB contact history (OR = 57.5; 95% CI = 6.1–545.1; $p = 0.0004$) were significantly associated with MDR-TB in armed force members. However, sex (OR = 1.0; 95% CI = 1.0–1.1; $p = 0.153$), age (OR = 5.1; 95% CI = 0.8–31.2; $p = 0.079$) and body mass index (OR = 1.0–6.9; 95% CI = 0.6–79.8; $p = 0.122–0.983$) were not the predicting factor for MDR-TB in armed force members.

In civilian patients, TB contact history has been found strong predicting factor for MDR-TB (OR = 0.04, 95% CI = 0.02–0.8; $p = 0.031$). However, sex (OR = 1.1; 95% CI = 0.1–17.4; $p = 0.965$), age (OR = 2.4; 95% CI = 0.14–38.9; $p = 0.546$), body mass index (OR = 0.6–3.4; 95% CI = 0.1–57.2; $p = 0.402–0.581$) and HIV infection (OR = 13.0; 95% CI = 0.7–227.8; $p = 0.079$) were not associated with MDR-TB in civilian patients.

Discussion
TB remains the major global health problem which ranked the 9th leading cause of death worldwide [1]. Currently, the emergency of MDR-TB is also the main public health problem in both developing and developed countries. Globally, the prevalence of MDR-TB case among the newly and previously treated TB patients has been found 3.5 and 20.5%, respectively [1]. The same WHO report also indicated that 7 African countries are listed out of 30 high burden MD-RTB countries in the world with the overall prevalence of 2.7% new and 14.0% previously treated cases [1].

In the current study, the overall prevalence of MDR-TB in armed force and civilian patients were identified 1.8%, in which all have been found previously TB treated patients. Although published data is deficient to compare this study with a similar setting (armed force + civilian), there is limited information reported in some countries focus on armed force patients (Table 5). Most of the studies found in the literature were civilian patients carried out in civilian hospital. The prevalence reports were in agreement with our study, particularly studies conducted in Indian (1.2%) and Turkey (2.7%) that focus on armed force patients (Table 5). A study on USA military population also stated that the incidence of TB disease identified in military population has been

| Table 2 | General demographic and clinical findings of civilian and armed force patients in AFRTH (Continued) |
|---------|--------------------------------------------------------------------------------------------------|
| Variables | Total cases $(n = 381)$ | Civilian $(n = 130)$ | Armed force members |
|          | No | % | No | % | No | % | No | % |
| Antiretroviral therapy status | | | | | | | | |
| ART started | 28 | 7.4 | 8 | 6.1 | 12 | 5.6 | 8 | 22.9 |
| ART not started | 6 | 1.6 | 1 | 0.8 | 3 | 1.4 | 2 | 5.7 |
| HIV negative | 321 | 84.2 | 105 | 80.8 | 191 | 88.4 | 25 | 71.4 |
| HIV not tested | 26 | 6.8 | 16 | 12.3 | 10 | 4.6 | 0 | 0 |

| Table 3 | Association of MDR-TB value in armed force and civilian TB patients in AFRTH |
|---------|--------------------------------------------------------------------------------------------------|
| Category | Total | MDR-TB | OR (95% CI) | $p$-value |
|          | $(n = 381)$ | + | – | |
| Active-Armed force | 216 | 2 | 214 | Ref | Ref |
| Pension-Armed force | 35 | 3 | 32 | 10.0 (1.6–62.4) | 0.013 |
| Civilian | 130 | 2 | 128 | 1.7 (0.2–12.0) | 0.610 |
| $p$-value | – | 0.007 ($\chi^2 = 9.86$) | – | – |
### Table 4 Factors associated with MDR-TB in AFRTH patients (armed force and civilian)

| Variables                  | Armed force members | Civilian |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |                  |
|----------------------------|---------------------|---------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
|                            | MDR-TB + | OR (95% CI) | p-value | MDR-TB + | OR (95% CI) | p-value | MDR-TB + | OR (95% CI) | p-value | MDR-TB + | OR (95% CI) | p-value | MDR-TB + | OR (95% CI) | p-value | MDR-TB + | OR (95% CI) | p-value |
| Sex                        |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |
| Female                     | 1       | 1.0 (1.0–1.1) | 0.153  | 1       | 1.1 (1.0–17.4) | 0.965  |         |           |         |         |           |         |         |           |         |         |           |         |
| Male                       | 4       | Ref       |         | 1       | Ref       |         |         |           |         |         |           |         |         |           |         |         |           |         |
| Age (year)                 |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |
| 18–44                      | 2       | 1.0 (0.9–11.5) | 0.983  | 0       | 0.6 (0.1–4.5) | 0.581  |         |           |         |         |           |         |         |           |         |         |           |         |
| ≥45                        | 3       | 5.1 (0.8–31.2) | 0.079  | 1       | 2.4 (0.14–38.9) | 0.546  |         |           |         |         |           |         |         |           |         |         |           |         |
| Body mass index (kg/m²)    |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |
| < 18.5                     | 2       | 6.9 (0.6–79.8) | 0.122  | 1       | 3.4 (0.2–57.2) | 0.402  |         |           |         |         |           |         |         |           |         |         |           |         |
| 18.5–25                    | 2       | 1.0 (0.9–11.5) | 0.983  | 0       | 0.6 (0.1–4.5) | 0.581  |         |           |         |         |           |         |         |           |         |         |           |         |
| > 25                       | 1       | Ref       |         | 2       | Ref       |         |         |           |         |         |           |         |         |           |         |         |           |         |
| History of TB contact      |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |
| No                         | 1       | Ref       |         | 1       | Ref       |         |         |           |         |         |           |         |         |           |         |         |           |         |
| Yes                        | 4       | 57.5 (6.1–545.1) | 0.0004 | 1       | 0.04 (0.02–0.8) | 0.031  |         |           |         |         |           |         |         |           |         |         |           |         |
| HIV result a               |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |         |           |         |
| Negative                   | 2       | Ref       |         | 1       | Ref       |         |         |           |         |         |           |         |         |           |         |         |           |         |
| Positive                   | 3       | 14.6 (2.3–92.1) | 0.004  | 1       | 13.0 (0.7–227.8) | 0.079  |         |           |         |         |           |         |         |           |         |         |           |         |

**OR** Odds ratio, **CI** Confident interval, **Ref** Reference

+ Positive, – Negative

*a16 from civil and 10 from armed force excluded

### Table 5 Comparing MDR-TB in this study with other previous findings

| Study area                  | Study population                  | Sample size (Number) | MDR-TB prevalence (%) | Reference |
|-----------------------------|-----------------------------------|----------------------|------------------------|-----------|
| TH in Addis Ababa, Ethiopia | Armed force members + civilian    | 381                  | 1.8                    | This study |
| Chest hospital in Istanbul, Turkey | Armed force members       | 365                  | 2.7                    | [32]      |
| Northwest, India            | Armed force members             | 172                  | 1.2                    | [27]      |
| Tertiary chest hospital, India | Armed force members       | 1120                 | 4.2                    | [30]      |
| AF capital hospital, Korea  | Armed force members (young)     | 198                  | 8.1                    | [8]       |
| Eastern, Ethiopia           | Civilian                         | 357                  | 1.1                    | [16]      |
| Northwest, Ethiopia         | Civilian                         | 124                  | 5.7                    | [21]      |
| Northeast, China            | Civilian                         | 205                  | 6.8                    | [33]      |
| Southeast, Nigeria          | Civilian                         | 180                  | 7.7                    | [34]      |
| Harare, Zimbabwe            | Civilian                         | 213                  | 12.0                   | [28]      |
| Sinaloa, Mexico             | Civilian                         | 671                  | 17.9                   | [35]      |
| Four regions, Swaziland     | Civilian                         | 633                  | 19.3                   | [29]      |
| Four sentinel sites, Georgia | Civilian                       | 931                  | 28.1                   | [36]      |
| Kassala, Sudan              | Civilian                         | 60                   | 30.0                   | [37]      |
| Omotia region, Ethiopia     | Civilian                         | 265                  | 33.2                   | [22]      |
| Amara region, Ethiopia      | Civilian                         | 413                  | 36.3                   | [20]      |
| Samara region, Russia       | Civilian + prisoner              | 600                  | 45.5                   | [38]      |

TH Tertiary hospital, AF Armed force, AFRTH Armed force referral and teaching hospital
found eight times lower (0.4 per 100,000) than the overall USA population (3.0 per 100,000) which supports the current study recorded lower MDR-TB infection [2]. Compared with the current study, relatively higher MDR-TB prevalence result also reported in Korean young armed force patients (Table 5). Compared with Ethiopian overall MDR-TB reported data (2.7% in newly and 14.0% in previously treated patients), the current MDR-TB prevalence result observed in AFRH is also found much smaller [1].

Except Seyoum et al. [16] reported lower (1.1%) MDR-TB prevalence, several other studies carried out in Ethiopia using civilians as a study participant was reported a higher result of MDR-TB results (Table 5). For instance, using civilian patients the prevalence of MDR-TB was 36.3% in Amara [20] and 33.2% in Oromia Regions [22] of Ethiopia. Compared with other countries study on MDR-TB prevalence using civilian society (Table 5), the current study also much lower than reports from Georgia (28.1%), Eastern Sudan (30.0%), Swaziland (19.3%), Zimbabwe (12.0%), Samara in Russia (45.5%) and Sinaloa in Mexico (17.9%).

The lower MDR-TB prevalence reported in this study primarily due to the variations in the selection of patient groups studied. In the present study, the subjects were civilian and armed force members. The armed force members were non-referred (living in Addis Ababa) and referred cases from various secondary command referral hospitals which are located in the different geographical location of the country. This makes the current study unique from surveys carried out by other workers mostly covering a particular geographical region using civilian subjects. The variation might also due to sample size, time of the study, access to health care facilities, and effectivesness of TB control programs. Compared to a remote area of Ethiopian health centers which deal with civilian population, there is an effective functioning of TB control program in military societies. The regular supplies of anti-tuberculosis drugs, well-organized patient diagnosis, treatment follow-up and good patient adherence are effectively implemented in armed forces which presumably contribute to the lower prevalence of MDR-TB in the current study. Indeed, this has been well reflected in the patient categories which include the civilian, pension and active armed members (Table 3).

With analysis of binary logistic regression model, the category of attendants showed a statistically significant difference with MDR-TB, particularly pension attendants were ten times more likely at risk for MDR-TB (OR = 10.0; 95% CI = 1.6–62.40; \( p = 0.013 \)) than active armed force members. However, the active military attendants and civilian patients didn’t show statistically significant (\( p = 0.610 \)) difference for MDR-TB positive result. Although it needs further investigation, the insignificant variation among active armed force and civilian attendants suggested that the later went to a tertiary level AFRTH for seeking better medical service that has been offered for limited private wing clients most probably in a better economic status. Previous studies showed that annual income status has been found a significant risk factor for MDR-TB prevalence [15, 25]. The statistical significance difference observed among pension and active military members were also most probably due to living environment/lifestyle and age of the patients. For example, health education (one time/week) and sanitation (two times/week) programs have been designed and implemented in active military societies that might help to reduce \( M. \) tuberculosis infection that aggravated due to poor hygiene and ventilation [15, 25]. Moreover, the early treatment made in active military society without any cost from the patient side might probably contribute to reducing the spread of drug-resistant TB in the community [26]. It is also clear that pension attendant is expected to have a high probability of developing MDR-TB than active military staff which is related to advancement in age [1]. Although not statistically significant (\( p = 0.079 \) and 0.546), advancement in age has been found 5 and 2 times more likely at risk for MDR-TB than younger age in armed force and civilian patients, respectively (Table 4). Moreover, pension attendants’ loss most of the active military privileges (such as health education, sanitation, early treatment and follow-up) which might enhance the probability of pension attendants contracted with TB bacteria that resist drug [11, 15, 25].

In this study, history of contact with TB patient has been found the predicting factor of MDR-TB for both armed force members (\( p = 0.0004 \)) and civilian (\( p = 0.031 \)) patients. When all cases (\( n = 381 \)) merged together and analyzed, pension (OR = 3.4; 95% CI = 1.0–12.1) and civilian attendant (OR = 1.5; 95% CI = 0.6–4.1) have a much higher risk of TB infected person contact than the active military staff which presumably suggested that the TB control is better managed in active military society through regular education about communicable and non-communicable diseases, and sanitation programs. Of course, \( M. \) tuberculosis is transmitted via close contact with an infected individual who is actively spreading the bacteria through coughing [1, 2]. Once inhaled, the infection is established with or without a visible primary lung lesion; lymphatic and hematogenous spread usually follows within 3 weeks of infection [2]. This study is in agreement with the study in USA military that mentioned higher TB risk among service members who may be exposed to infected persons, such as personnel involved in humanitarian assistance and health care operations serving local, high-risk populations [2].

Among 381 TB suspected patients, the new and retreatment TB cases that showed growth on the media
were found 71.1 and 6.8%, respectively. However, 11.8% of culture positive samples did not found smear positive. The growth of *M. tuberculosis* on LJ media in cases of smear negative for acid-fast bacilli is a known phenomenon as \(10^5\) bacilli per mL of sputum are required for the organism to be seen on light microscope but culture may show growth [27].

In the current study, the number of HIV positive and negative patients were identified 34 (9.6%) and 321 (90.4%) for all patients tested, respectively. Compared with other studies [28, 29] in Swaziland (22.6% = 102/451) and Zimbabwe (74.0% = 157/211), HIV positive patients are relatively lower in this study (25/241 in armed force members and 9/114 in civilian patients). However, the HIV positive results were found a significant predicting factor for MDR-TB (OR = 14.6; 95% CI = 2.3–92.1; \(p = 0.004\)) in armed force members. Particularly, the infection is magnificent in pension attendants (10 out of 25) (Table 3), suggested that during the study period the pension staff with HIV might frequently register at AFRTH for medical service which is provided free as a staff member. Moreover, pension staffs are at the older age in which much of the physiological activities are downgraded and contributed to the co-infection of HIV-TB under immunocompromised conditions [28, 29]. Statistical analysis also showed that there was a positive significant correlation between MDR-TB and HIV co-infection (\(r = 0.229\); \(p < 0.01\)).

In the current study, the status of 284 (74.5%) patients was identified while 97 (25.5%) patients transferred out and status unknown. Among the status identified patients, the treatment success rate was found 93.0%, highest in active armed force followed by pension and civilian patients (Table 2). The higher rate of treatment success in armed force patients most probably indicates that there is a good efficacy of the standard treatment regimen in armed force society. The adequate follow-up, early identification and management of adverse drug reactions had been mentioned the key to favorable treatment outcome success [26, 30]. Drug sensitive pulmonary TB is generally treated with four active drugs isoniazid, rifampin, pyrazinamide and ethambutol [17]. These drugs are continued for the first 2 months of therapy and are subsequently followed by at least 4 mo of two drugs (most commonly with isoniazid and rifampin). There was no default cases observed in the current study. However, 7.0% treatment failure rate was attributed due to death and failure cases. Similar to this study, 9.0% failure rate (dead and failure) was recorded in Germany [31]. However, higher treatment failure rate was observed in other studies in civilian hospitals [20, 26, 29], suggesting that TB drug administration in AFRTH is implemented efficiently.

Our retrospective study has limitations. Since reports were not designed for study purposes, some demographic MDR-TB predicting factors such as annual income, size of living space, family history, history of prison and others were lacking. The clinical treatment outcome of referred outpatients to secondary level command hospitals was not identified. Follow-up time was recorded to the completion of treatment at AFRTH. Although this time frame is sufficient for documenting surveillance-based treatment outcomes, it may not be sufficient to assess long-term clinical outcomes. It was also difficult to distinguish the referred patient where they came (which military command hospital) that might help to identify which geographical location contributed more to MDR-TB case and plan better management. Despite these limitations, the current study provides information about the MDR-TB prevalence and associated factors in AFRTH where data has not been previously published. Moreover, comparative studies among armed force members (active and pension) and civilian patients also unique to this study to provide information about MDR-TB.

**Conclusions**

MDR-TB is a major public health problem and mainly affects economically productive age group of the population. Compared with many civilian hospitals, the prevalence of MDR-TB in AFRTH was found low. This shows that TB control management is well implemented in armed society. In general, this study might be scale-up and applicable all over in Ethiopia and elsewhere in the world, where information is scant (armed force society) to improve the availability and quality of MDR-TB service.

**Abbreviations**

AF: Armed force; AFRTH: Armed force referral and teaching hospital; ART: Antiretroviral therapy; CI: Confidence interval; DST: Drug susceptibility testing; HIV: Human immunodeficiency virus; HMD: Health main directorate; LJ: Lowenstein Jensen; MDR-TB: Multidrug-resistant tuberculosis; OR: Odds ratio; Ref: Reference; SPSS: Statistical package for the social sciences; TB: Tuberculosis; TH: Tertiary hospital; WHO: World Health Organization

**Acknowledgments**

The authors would like to thank Armed Force Health Main Directorate giving permission to carry out this research. We would also like to extend our appreciation to Armed Force Referral and Teaching Hospital staff members for their cooperation.

**Availability of data and materials**

All data analyzed during this study are included in this published article. Raw data is also available from the corresponding author and will be shared upon reasonable request.

**Authors’ contributions**

BD participated in the design of this study, collect data and draft the manuscript. AZ, HS, and SX participated in revising the manuscript. AG participated in the design of this study, wrote the manuscript, interpreting the results and discussion. All authors have read and approved the final manuscript.

**Ethics approval and consent to participate**

The current investigation followed the tenets of the Declaration of Helsinki and ethical clearance was obtained from Health Main Directorate in Armed Force Referral and Teaching Hospital. Before the investigation was performed, written informed consent was obtained from all study participants about their information to be used for research purposes.
Competition interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Ophthalmology, Shanghai Tenth People’s Hospital, Tongji University, School of Medicine, Shanghai, China. 2Department of TB/HIV, Armed Force Referral and Teaching Hospital, Addis Ababa, Ethiopia. 3State Key Laboratory of Pollution Control and Resource Reuse, College of Environmental Science and Engineering, Tongji University, Shanghai, China. 4Department of Biology, College of Natural Sciences, Arba Minch University, P.O. Box 21, Arba Minch, Ethiopia.

Received: 5 March 2018 Accepted: 25 May 2018

Published online: 31 May 2018

References

1. World Health Organization. Global tuberculosis report. Geneva: World Health Organization; 2017.
2. Sanchez JL, Sanchez JL, Cooper MJ, Hiser MJ, Mancuso JD. Tuberculosis as a force protection threat to the United States military. A review Mil Med. 2015;180:276–84.
3. World Health Organization. Tuberculosis fact sheet N°104. Revised March 2006. Available at: http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 18 Dec 2017.
4. Kent PI, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Atlanta: Center for disease control; 1985.
5. World Health Organization. Global tuberculosis control report. 20th ed. Geneva: World Health Organization; 2015.
6. Sanchez JL, Jean K, Kim KH, Min KH. Multidrug-resistant pulmonary tuberculosis among young Korean soldiers in a communal setting. J Korean Med Sci. 2009;24:592–5.
7. Federal Ministry of Health (FMOH), Ministry of Health of Ethiopia. Tuberculosis, leprosy and TB/HIV Prevention and Control program manual. 4th ed. Addis Ababa Federal Ministry of Health; 2008.
8. Lee SW, Jeon K, Kim KH, Min KH. Multidrug-resistant pulmonary tuberculosis among young Korean soldiers in a communal setting. J Korean Med Sci. 2009;24:592–5.
9. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis 2014. Version March 2010; available at http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf. Accessed 20 May 2018.
10. Yuan Y, Zhu Y, Crane DD, Barry CE. The effect of oxygenated mycolic acid Mycobacterium tuberculosis with RpoB mutation H526D. Front Microbiol. 2018;9:494.
11. Pal R, Fatima Z, Hameed S. Efflux pumps in drug resistance of Mycobacterium tuberculosis. Int J Curr Microbiol App Sci. 2014;3:528–46.
12. Nguyen L. Antibiotic resistance mechanisms in M. tuberculosis: an update. Arch Toxicol. 2016;90:585–604.
13. Chen W, Biswas T, Porter VR, Tsotkoiv OV, Ganeaau-Tsotkoiv S. Unusual regionality of acetyltransferase Eai, a cause of drug resistance in XDR-TB. Proc Natl Acad Sci U S A. 2011;108:9804–8.
14. Chen S, Hui P, Wang X, Zhong J, Wang X, Wang K, Wang L, Jiang S, Li J, Peng Y, Ma W. Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case–control study. Int J Infect Dis. 2013;17(12):e1116–20.
15. Li W, Zhang YQ, Xing J, Ma ZY, Qu YH, Li XX. Factors associated with primary transmission of multidrug-resistant tuberculosis compared with healthy controls in Henan Province, China. Infect Dis Poverty. 2015;4:14.
16. Seyoum B, Demisie M, Worku A, Bekete S, Asetfa A. Prevalence and drug resistance patterns of Mycobacterium tuberculosis among new smear positive pulmonary patients in eastern Ethiopia. Tuberc Res Treat. 2014;2014:1–7.
17. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis 2014. Version March 2010; available at http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf. Accessed 20 May 2018.

18. Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O’Grady J, Hoelscher M, Zumla A. Review of multidrug resistant and extensively drug resistant TB: global perspectives with a focus on sub-Saharan Africa. Tropical Med Int Health. 2010;15:1052–66.
19. Ben AV, Nemser B, Singh A, Sankin A, Schlueger N. Under reported threat of multidrug-resistant tuberculosis in Africa. Emerg Infect Dis. 2008;14:1345–52.
20. Mekonnen D, Admasu A, Mulu W, Amor A, Benito A, Gelaye W, Baddegfene F, Abera B. Multidrug-resistant and heteroresistant Mycobacterium tuberculosis and associated gene mutations in Ethiopia. Int J Infect Dis. 2015;39:34–8.
21. Mekonnen F, Tessema B, Muges F, Gelaye A, Esthetie S, Kumerga G. Multidrug resistant tuberculosis: prevalence and risk factors in districts of metema and west armachicho, Northwest Ethiopia. BMC Infect Dis. 2015;15:1–6.
22. Mulisa G, Worneh T, Hordofa N, Sauidi M, Abebe G, Jarso G. Multidrug-resistant Mycobacterium tuberculosis and associated risk factors in Oromia region of Ethiopia. Int J Infect Dis. 2015;39:57–61.
23. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 4th ed. Geneva: World Health Organization; 2009.
24. Kent PI, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. Atlanta: Center for disease control; 1985.
25. Wang K, Chen S, Wang X, Zhong J, Wang X, Huai P, Wu L, Wang L, Jiang S, Li J, Peng Y, Yao H, Ma W. Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case–control study from China. Microb Drug Resist. 2014;20:294–300.
26. Kliner M, Canaan M, Ndawndwe SZ, Busulwa F, Welfare W, Richardson M, Walley I, Wright J. Effects of financial incentives for treatment supporters on tuberculosis treatment outcomes in Swaziland: a pragmatic interventional study. Infect Dis Poverty. 2015;4:29.
27. Chand K, Khandelwal R, Vardhan V. Resistance to anti-tuberculosis drugs in pulmonary tuberculosis. Med J Armed Forces India. 2006;62:325–7.
28. Metcalfe JZ, Makumbirofa S, Makamure S, Sandy C, Bara W, Mungufa C, Hopewell PC, Mason P. Drug-resistant tuberculosis in high-risk groups, Zimbabwe. Emerg Infect Dis. 2014;20:135–7.
29. Sanchez-Padilla E, Damloni T, Ascorra A, Rüsch-Gerdes S, Tefera ZD, Calpin P, de la Tour R, Joehms F, Richter E, Bonnet M. High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009–2010. Emerg Infect Dis. 2012;18:29–37.
30. Chand K, Tewari SC, Varghese SJ. Prevalence of drug resistance tuberculosis in armed forces: a study from tertiary referral chest diseases hospital at Pune. Med J Armed Forces India. 2005;61:130–4.
31. Eker B, Ottrmann M, Migliori GB, Sotigli G, Muettlerin R, Centis R, Hoffmann K, Kistn D, Schaberg T, Ruesch-Gerdes S, Lange C. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis. 2008;14:700–6.
32. Kartaloglou Z, Bozkanat E, Okturk I, Olcut D, Ivan A. Primary anti-tuberculosis drug resistance at Turkish military chest disease hospital in Istanbul. Med Princ Pract. 2002;11:202–5.
33. Yang Y, Zhou Z, Shi L, Meng H, Yan H. Prevalence and characterization of drug-resistant tuberculosis in a local hospital of Northeast China. Int J Infect Dis. 2014;20:135–7.
34. Uzoewulu NG, Ibeh IN, Lawson L, Goyal M, Umenyonu N, Ofiaeli RO, Velazquez-Roman J, Flores-Villaseñor H, Canizalez-Roman A. Increasing drug resistance of Mycobacterium tuberculosis in Sinaloa, Mexico, 1997–2005. Int J Infect Dis. 2011;15:272–6.
35. Mvungi N, Zangaladze E, Volkova N, Kourbatova E, Thea Kutateladze T, Khechinashvili G, del Rio C, Salakaia A, Blumberg HM. High prevalence of multidrug-resistant tuberculosis: prevalence and risk factors in districts of metema and west armachicho, Northwest Ethiopia. BMC Infect Dis. 2015;15:1–6.
36. Mdivani N, Zangaladze E, Volkova N, Kourbatova E, Thea Jibuti T, Shubladze N, Golishevskaya V, Erokhin V, Dorozhkova I, Drobniewski F. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara region, Russia. Thorax. 2005;60:130–5.